Dr. Reddy’s Laboratories subsidiary Promius Pharma has launched Zembrace SymTouch in the US to treat patients with acute migraine.
Migraine is a primary headache disorder characterised by recurrent headaches that are moderate to severe. Its associated symptoms include nausea, vomiting, and sensitivity to light, sound, or smell.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The headaches affect one half of the head and are pulsating in nature, and last from two to 72 hours.
Promius’ Zembrace SymTouch is a prefilled, low-dose, ready-to-use, two-step autoinjector that contains 3mg of sumatriptan, a selective 5-HT1B/ID receptor agonist.
This prescription medicine is used to treat acute migraine headaches with or without aura in adults who have been diagnosed with a migraine. It is not used to prevent or decrease the number of migraines.
National Headache Foundation associate executive chairman Roger Cady said: "Zembrace SymTouch is a welcome addition to the toolkit for acute treatment of migraine.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"This 3mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks.
"Also, the 3mg dose allows for up to four doses of Zembrace SymTouch in a 24-hour period, therefore allowing dosing flexibility for patients."
The launch comes on the heels of approval from the US Food and Drug Administration (FDA) in January this year.
Zembrace SymTouch is not recommended for people with risk factors for heart disease unless a heart exam is done and shows no problem.
